A phase I, open-label modified 3+3 dose escalation study of autologous T-cells genetically engineered with an affinity optimized MAGE-A4 TCR in HLA*02 positive patients

Trial Profile

A phase I, open-label modified 3+3 dose escalation study of autologous T-cells genetically engineered with an affinity optimized MAGE-A4 TCR in HLA*02 positive patients

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Cell therapies (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Jan 2017 According to an Adaptimmune media release, the US Food and Drug Administration (FDA) has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing an affinity optimized T-cell receptor (TCR) specific for MAGE-A4 in patients with multiple malignant solid tumors.
    • 29 Aug 2016 New trial record
    • 08 Aug 2016 According to an Adaptimmune media release, the company is on track to submit an IND for MAGE-A4 SPEAR T-cell therapy for treatment of multiple tumour types in the first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top